The Phase I Trial of IPI-145 in Hematologic Malignancies

Video

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3K-delta and PI3K-gamma.

IPI-145 showed remarkable activity in hematologic malignancies in a phase I trial. At the 2013 American Society of Clinical Oncology Meeting, it was announced that a phase II trial would take place, looking to accrue 120 patients with indolent non-Hodgkin lymphoma in the relapsed/refractory setting.

The phase I trial had two portions. First, the dose-escalation phase enrolled 33 patients between 8mg and 100mg, defining 75mg as the maximum-tolerated dose. In the second phase, 25mg and 75mg cohorts showed potent activity in blocking phosphorylation of AKT and downstream chemokine and cytokines. Both doses have shown a great deal of activity across a broad spectrum of hematologic malignancies.

Data are still maturing in this trial, Adams notes, but responses were observed of about 68% in indolent non-Hodgkin lymphoma. In chronic lymphocytic leukemia (CLL), a 55% response rate was observed, with an additional 35% nodal response. The trial is not as far along in T-cell malignancies, but good responses have been seen in patients with Sezary syndrome and patients with peripheral T-cell lymphoma.

Clinical Pearls

IPI-145 has been generally well tolerated in this space, with no dose-related adverse events. Sporadic adverse events have been observed due to comorbidities associated with CLL and lymphoma, though this is to be expected, Adams says.

  • IPI-145 is a potent inhibitor of PI3K-delta and PI3K-gamma
  • In a phase I trial, the drug showed activity across a broad spectrum of hematologic malignancies
  • There was about a 68% response rate in an early assessment of indolent non-Hodgkin lymphoma and 55% in chronic lymphocytic leukemia
  • IPI-145 has been generally well tolerated by patients, with no dose-related adverse events

<<<

View all coverage from the 2013 ASCO Meeting

Related Videos
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Related Content